Lexicon Pharmaceuticals, Inc.  

(Public, NASDAQ:LXRX)   Watch this stock  
Find more results for LXRX
14.21
+0.53 (3.87%)
After Hours: 14.21 0.00 (0.00%)
May 31, 4:36PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.52 - 14.23
52 week 6.91 - 15.79
Open 13.61
Vol / Avg. 871,001.00/699,813.00
Mkt cap 1.50B
P/E     -
Div/yield     -
EPS -0.20
Shares 103.82M
Beta 1.37
Inst. own 107%
Aug 5, 2016
Q2 2016 Lexicon Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 11, 2016
Lexicon Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 3, 2016
Q1 2016 Lexicon Pharmaceuticals Inc Earnings Call
May 3, 2016
Q1 2016 Lexicon Pharmaceuticals Inc Earnings Release
Apr 28, 2016
Lexicon Pharmaceuticals Inc Annual Shareholders Meeting
Apr 22, 2016
Lexicon Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Apr 12, 2016
Lexicon Pharmaceuticals Inc at Needham Healthcare Conference
Mar 9, 2016
Lexicon Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -279.20% -3.60%
Operating margin -271.10% 1.13%
EBITD margin - 4.45%
Return on average assets -22.15% -0.83%
Return on average equity -51.94% -1.64%
Employees 120 -
CDP Score - -

Address

8800 Technology Forest Pl
THE WOODLANDS, TX 77381-1160
United States - Map
+1-281-8633000 (Phone)
+1-281-8638088 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company's other programs include LX1033, LX2931 and LX7101.

Officers and directors

Raymond Debbane Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Lonnel Coats President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Jeffrey L. Wade J.D. Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
Age: 50
Bio & Compensation  - Reuters
Pablo Lapuerta M.D. Executive Vice President, chief medical officer
Age: 51
Bio & Compensation  - Reuters
Alan J. Main Ph.D. Executive Vice President - CMC and supply operations
Age: 61
Bio & Compensation  - Reuters
Praveen Tyle Ph.D. Executive Vice President of Research and Development
Age: 56
Bio & Compensation  - Reuters
James F. Tessmer Vice President - Finance & Accounting
Age: 55
Bio & Compensation  - Reuters
John Northcott Vice President - Marketing, Commercial Strategy and Operations
Age: 37
Bio & Compensation  - Reuters
Philippe J. Amouyal Independent Director
Age: 57
Bio & Compensation  - Reuters
Samuel L. Barker Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters